0.500
0.00 (-0.38%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Bullish |
| Diagnostics & Research (Global) | Bullish | Bullish | |
| Stock | 23andMe Holding Co. | Bearish | Bearish |
|
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Newview Capital Partners I, Llc | 31 Dec 2023 | 19,455,681 |
| Euclidean Capital Llc | 31 Dec 2023 | 10,243,122 |
| Sapphire Ventures, L.L.C. | 31 Dec 2023 | 5,291,824 |
| Alibaba Group Holding Ltd | 31 Dec 2023 | 2,118,444 |
| Wittenberg Investment Management, Inc. | 31 Dec 2023 | 1,397,393 |
| 52 Weeks Range |
0.350 - 2.21
|
|
| High | 0.470 (Citigroup, -6.06%) | Hold |
| Median | 0.470 (-6.06%) | |
| Average | 0.470 (-6.06%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 16 Apr 2024 | 0.470 (-6.06%) | Hold | 0.390 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |